Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
PRECISION BIOSCIENCES INC (DTIL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ASSET PURCHASE AGREEMENT BY AND AMONG PRECISION BIOSCIENCES, INC., IMUGENE INC. and IMUGENE LIMITED August 15, 2023",
"Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between IMUGENE INC. and PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT This License Agreement is entered into as of August 15, 2023 , by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. , and Imugene Inc., a corporation organized and existing under the laws of Nevada, with its principal business office located at Suite 200, 701 South Carson St, Carson City, Nevada 89701, U.S.A. . Imugene and Precision are each hereafter referred to individually...",
"Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements On August 15, 2023, Precision BioSciences, Inc. entered into an Asset Purchase Agreement with Imugene Limited, an Australian corporation , and its wholly owned subsidiary Imugene Inc. , a Nevada corporation . Pursuant to and simultaneously with the execution of the Purchase Agreement, on August 15, 2023 , Imugene US acquired the manufacturing infrastructure to the Company’s CAR T program that uses azer-cel for the potential treatment of relapsed or refractory non-Hodgkin lymphoma, which includes the Company’s MCAT facility, certain contracts of the Company with respect to the MCAT facility and the Company’s azer-cel program, including the lease to the MCAT facility, and related equipment, supplies, ..."
08/04/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update - FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing - Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B - Company plans to host In Vivo Gene Editing R&D Day on September 12, 2023 - Cash Balance Provides Expected Runway Through Q1 2025"
07/06/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. EXECUTION VERSION amended and restated DEVELOPMENT AND LICENSE AGREEMENT between PREVAIL THERAPEUTICS INC. and PRECISION BIOSCIENCES, INC. AMENDED AND RESTATED Development AND LICENSE AGREEMENT This Amended and Restated Development and License Agreement entered into as of June 30, 2023 , by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. , and Prevail Therapeutics Inc., a corporation organized and existing under the laws of Delaware, with its principal business office..."
05/31/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events Were Observed Azer-Cel Achieved 83% Overall Response Rate , 61% Complete Response Rate with 55% Durable Response Greater Than or Equal to Six Months Among Evaluable CAR T Relapsed Subjects Upcoming Azer-Cel Meeting with FDA in June to Align on Potential Phase 2 Study in CAR T Relapsed Diffuse Large B-cell Lymphoma ; Focus on Trial Design, Size, and Endpoints PBCAR19B Stealth Cell Proof of Concept Achieved; Designed to Enable Expansion and Persistence by Delaying Host Rejection Throug..."
05/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update - Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference - In Vivo Gene Editing R&D Day Planned for Mid-2023 - Cash Balance Provides Expected Runway through Q1 2025"
04/28/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
04/18/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical Studies; Program Updates Planned for Azer-cel and PBCAR19B - Advanced Wholly Owned, Preclinical PBGENE-HBV and Partnered DMD, Sickle Cell Disease, and OTC Programs; New Data Expected to be Presented/Published in 2023 - Cash Balance Provides Expected 2-Year Runway through Q1 2025"
02/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact:"
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Investor Contact:"
11/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact: Mei Burris Director, Investor Relations and Finance"
11/08/2022 8-K Quarterly results
Docs: "Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 - Abstract Showcasing Functional Attributes of Azer-cel Accepted for Presentation at the 64th American Society of Hematology Annual Meeting - Preclinical Research on In Vivo Gene Editing Programs Presented at the European Society of Gene & Cell Therapy 29th Congress - Strong Cash Position Provides More than Two Years of Expected Runway"
09/02/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact:"
08/08/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/11/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
03/15/2022 8-K Quarterly results
Docs: "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update -"
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Precision BioSciences to Present at the 40 th Annual J.P. Morgan Health Care Conference"
12/21/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Precision BioSciences Completes Spin-Out of Elo Life Systems"
12/13/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update -"
11/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience"
10/21/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021"
09/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Michael Amoroso and Precision Biosciences, Inc",
"Precision BioSciences Appoints Michael Amoroso Chief Executive Officer",
"Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635"
09/09/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline -",
"Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE"
08/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy